Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma. 

Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted in transplant-ineligible patients with high risk of rapid disease progression. 

“Zamto-cel demonstrated clinically meaningful and statistically significant superiority over R-GemOx in transplant-ineligible patients with high-risk disease, improving event-free survival while maintaining a favourable tolerability profile,” said Dr Peter Borchmann, Lead investigator of the trial and Assistant Medical Director in the Department of Haematology and Oncology at the University Hospital of Cologne, Germany. 

“These findings highlight the potential of zamto-cel as an important new treatment option for a clinically vulnerable patient population with limited therapeutic choices.” 

“The DALY 2-EU results mark an important milestone in our commitment to advancing cell and gene therapies,” added Dr Toon Overstijns, Chief Executive Officer of Miltenyi Biomedicine. 

“Zamto-cel – the first tandem CD20-CD19 (directed), non-cryopreserved CAR-T cell therapy – demonstrated meaningful clinical benefit with promising efficacy and safety, bringing us closer to providing much needed treatment options for patients with high-risk lymphomas.”